Providing High Value, OTC Drugs Deserve Higher Profile In Health Care – CHPA
While Rx drug pricing is under attack by Congress, White House and consumer and public health advocacy groups, OTC drugs' value isn't gaining a higher profile. "Our health care system undervalues the contribution of our industry's products," says CHPA chief Scott Melville. Trade group conducts “Value of OTC Medicines" study for reasons including raising the profile of consumer health products in the US health care system.
You may also be interested in...
Health And Wellness Industry News: Restoring Access Bill Introduced, Another Dietary Fiber Meets FDA Definition, More
Restoring Access to OTC bill introduced; West Virginia is 18th state to prohibit sales of DXM-containing cough suppressant to minors without a prescription; American Botanical Council presents Norman R. Farnsworth Excellence Award to Swiss pharmacist Otto Sticher; FDA adds another fiber to definition of dietary fiber; and Jarrow probiotics top ConsumerLab brand survey.
Many CHPA members also market medical devices "and the consumer side of medical devices is something they feel is underrepresented by other trade associations,” says trade group head Scott Melville. OTC drugs already have “a lot in common” with consumer medical devices, including that paying for neither typically is included in health insurance plans.
Commissioner Gottlieb has been a “very strong champion” of FDA and his interest in improving the OTC monograph and switch processes provides hope to the industry during a tumultuous legislative era, say CHPA executives at their annual meeting in Florida. They expect monograph reform will happen this year but doubt much else will happen before mid-term elections in November.